Benzinga · Aug 6, 2026
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120
HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $118 to $120.
IR
NASDAQ · IRON
Disc Medicine, Inc.
Healthcare · Biotechnology
$80.05
Up+$1.38 (+1.75%)
Updated Sep 3, 2026, 11:57 AM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.53B
- P/E ratio
- -18.17
- Dividend yield
- 0.00%
- 52-week range
- $40.00 – $99.50
- Volume
- 522.55K
- Avg. volume
- 503.23K
Price performance
IRON price history
1M range · 21 trading sessions · Daily adjusted prices
IRON closed at $80.05 after 21 trading sessions, up 1.44% for the selected period.
- Last close
- $80.05
- Period change
- +1.44%
- Period low
- $77.44
- Period high
- $82.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $79.44 | $81.01 | $77.6804 | $80.05 | 522.55K |
| Sep 1, 2026 | $78.56 | $79.95 | $75.88 | $78.67 | 549.44K |
| Aug 31, 2026 | $79.19 | $80.525 | $77.50 | $78.65 | 882.04K |
| Aug 28, 2026 | $81.79 | $82.70 | $79.77 | $80.03 | 665.58K |
| Aug 27, 2026 | $82.25 | $83.195 | $81.10 | $82.55 | 324.13K |
| Aug 26, 2026 | $82.28 | $83.63 | $81.54 | $82.67 | 586.89K |
| Aug 25, 2026 | $81.99 | $83.59 | $81.77 | $82.41 | 320.94K |
| Aug 24, 2026 | $79.88 | $82.74 | $79.33 | $80.94 | 277.24K |
| Aug 21, 2026 | $79.50 | $80.00 | $77.99 | $79.81 | 370.35K |
| Aug 20, 2026 | $79.45 | $80.145 | $78.49 | $78.84 | 333.63K |
| Aug 19, 2026 | $81.91 | $81.99 | $79.59 | $80.32 | 457.25K |
| Aug 18, 2026 | $79.67 | $81.41 | $78.65 | $80.20 | 337.17K |
| Aug 17, 2026 | $78.53 | $80.09 | $74.46 | $80.05 | 384.21K |
| Aug 14, 2026 | $79.53 | $80.65 | $77.99 | $78.84 | 262.58K |
| Aug 13, 2026 | $81.32 | $81.32 | $79.405 | $80.01 | 340.96K |
| Aug 12, 2026 | $81.41 | $83.1185 | $79.96 | $80.59 | 263.48K |
| Aug 11, 2026 | $79.04 | $81.42 | $78.22 | $81.21 | 254.56K |
| Aug 10, 2026 | $77.44 | $78.78 | $75.7911 | $78.28 | 308.43K |
| Aug 7, 2026 | $78.36 | $78.79 | $76.785 | $77.44 | 307.55K |
| Aug 6, 2026 | $79.66 | $80.99 | $76.57 | $77.44 | 323.97K |
| Aug 5, 2026 | $78.39 | $79.60 | $76.69 | $78.91 | 272.31K |
Latest IRON news
The latest Smart Investors Daily articles mentioning IRON.
Stock researchCompany · Overview
IRON research
Overview
Company profile and research snapshot.
Company profile
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $123.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Wedbush | Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 16, 2026 | Morgan Stanley | Overweight | — |
| Jun 10, 2026 | Wedbush | Outperform | — |
| May 14, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Jul 30, 2026
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded Access Program (EAP) for bitopertin for eligible erythropoietic protoporphyria (EPP) patientsPresented positive clinical data updates from the RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis and the HELIOS open-label extension trial of bitopertin in EPPCompleted enrollm
Benzinga · Jul 30, 2026
Disc Medicine Q2 EPS $(1.54) Beats $(1.77) Estimate
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.54) per share which beat the analyst consensus estimate of $(1.77) by 12.99 percent. This is a 2.53 percent increase over losses of $(1.58) per share from the
SeekingAlpha · Jul 21, 2026
Going Deeper On Disc Medicine
Disc Medicine stock is slightly compelling, trading at ~$2.1 billion net of cash, with significant upside tied to bitopertin and DISC-0974 clinical milestones. Read the full analysis here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
